Cytokine Innovation in IBD Report
Key insights included:
- Rising clinical engagement: IBD-related cytokine research has surged, with 568 trials now tracked on Beacon and 52% of 2025 starts already recruiting.
- Expanding therapeutic landscape: Beacon Cytokine monitors 238 drugs in IBD, 19% approved and 28% in active development.
- Leading targets: TNF-alpha remains the most active cytokine target, with therapies like Infliximab continuing to drive innovation through real-world studies.
- …and much more inside the report!
You May Also Be Interested In…
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
